Premium
The pharmacokinetics and pharmacodynamics of enoxaparin in obese volunteers
Author(s) -
Sanderink GerJan,
Le Liboux Aimé,
Jariwala Navin,
Harding Neasa,
Ozoux MarieLaure,
Shukla Umesh,
Montay Guy,
Boutouyrie Bruno,
Miro Adelaida
Publication year - 2002
Publication title -
clinical pharmacology and therapeutics
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.941
H-Index - 188
eISSN - 1532-6535
pISSN - 0009-9236
DOI - 10.1067/mcp.2002.127114
Subject(s) - medicine , pharmacokinetics , partial thromboplastin time , pharmacodynamics , crossover study , volume of distribution , low molecular weight heparin , confidence interval , anesthesia , adverse effect , pharmacology , heparin , placebo , coagulation , pathology , alternative medicine
Objectives The objective of this study was to compare the pharmacokinetics of the low‐molecular‐weight heparin enoxaparin in obese and nonobese volunteers, by means of two administration regimens. Methods Enoxaparin was administered subcutaneously (1.5 mg/kg once daily for 4 days) and in a single 6‐hour infusion (1.5 mg/kg) to 24 obese volunteers and 24 age‐, sex‐, and height‐matched nonobese volunteers in a randomized, open‐label, 2‐way crossover design. Blood plasma was assessed for anti‐Xa and anti‐IIa activity and activated partial thromboplastin time. Results After subcutaneous administration, steady‐state exposure was achieved after the second dose in nonobese volunteers and after the third dose in obese volunteers. Time to maximum anti‐Xa activity was 1 hour longer in obese volunteers, but maximum anti‐Xa activity was similar in both groups. For anti‐Xa activity, exposure at steady‐state was 16% higher in obese volunteers than in nonobese volunteers (90% confidence interval, 108%‐125%). After intravenous infusion, total body clearance and volume of distribution at steady state were higher in obese volunteers than in nonobese volunteers, but when adjusted for weight, these values were about 10% lower in obese volunteers. Anti‐IIa activity after subcutaneous administration did not differ significantly between obese and nonobese volunteers. Pharmacodynamic analysis of activated partial thromboplastin time showed similar results in obese and nonobese volunteers after both intravenous and subcutaneous administration. No deaths or serious adverse events occurred during the study. Conclusions Enoxaparin was well tolerated when administered subcutaneously or intravenously, and there appears to be no need to modify the currently recommended dose for obese volunteers. Clinical Pharmacology & Therapeutics (2002) 72 , 308–318; doi: 10.1067/mcp.2002.127114